Furthermore, combining senolytic therapy to prevent tumor‐specific T cell senescence with anti‐PD‐L1 checkpoint blockade has also been found to synergistically enhance anti‐tumor immunity and improve immunotherapy outcomes in vivo (Liu et al. 2022). Here, CD274 is linked to neoplasm.